{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/candida-female-genital/background-information/risk-factors/","result":{"pageContext":{"chapter":{"id":"c7dd35c5-dc87-55a0-b15e-5fd3c5f79ede","slug":"risk-factors","fullItemName":"Risk factors","depth":2,"htmlHeader":"<!-- begin field b43dda34-66af-47fd-9a66-43e9fa038d9c --><h2>What are the risk factors?</h2><!-- end field b43dda34-66af-47fd-9a66-43e9fa038d9c -->","summary":"","htmlStringContent":"<!-- begin item b684ecc8-4f08-4474-9796-9c01ed77276f --><!-- begin field 50298c6c-aa57-4ab2-b36e-74d94f7016bc --><ul><li><strong>The risk factors for uncomplicated vulvovaginal candidiasis include: </strong><ul><li><strong>Oestrogen exposure </strong>— oestrogen is thought to play an essential role in the development of vulvovaginal candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Nwokolo and Boag, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Fischer, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">FSRH, 2012</a>]; therefore, the condition is more common during the reproductive years and during pregnancy.<ul><li>The incidence rises rapidly after the menarche and peaks in the third and fourth decade of life. Pre-pubertal girls and postmenopausal women rarely have vulvovaginal candidiasis without an underlying predisposing factor [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Sobel, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Hayes and Creighton, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Sobel, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Fischer and Bradford, 2016</a>].</li><li>During pregnancy, asymptomatic vaginal colonization with <em>Candida</em>, acute vulvovaginal candidiasis, recurrent infection, and treatment failure are all more common [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>].</li></ul></li><li><strong>Immunocompromised state </strong>— vulvovaginal candidiasis is common (and recurs frequently) in women who are immunocompromised, for example women with HIV infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Ray et al, 2011</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Nelson et al, 2011</a>]. However, it is no more severe in this group than in women without HIV [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Duerr et al, 2003</a>].</li><li><strong>Poorly controlled diabetes mellitus </strong>— the risk of symptomatic vulvovaginal candidiasis is increased in women with poorly managed diabetes. Women without diabetes who have recurrent vulvovaginal candidiasis tend to have substantially higher blood glucose levels (but still within the normal range). The prevalence of vulvovaginal candidiasis is not increased in women with well-controlled diabetes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Sobel, 2007</a>].</li><li><strong>Treatment with broad-spectrum antibiotics </strong>— vulvovaginal candidiasis occurs in about 30% of women taking a course of systemic or intravaginal antibiotics. However, only women who are already colonized with <em>Candida</em> are at risk of vulvovaginal candidiasis following treatment with antibiotics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Sobel, 2007</a>].</li><li><strong>Local irritants </strong>— expert opinion in guidelines is that local irritants (such as soaps, shower gels, and ‘feminine hygiene’ products) and tight-fitting, synthetic clothing can predispose to (or exacerbate) symptomatic vulvovaginal candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">FSRH, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCGP, 2013</a>], but the evidence for these is limited, conflicting, or absent. Evidence from observational studies suggests that vaginal douching increases the risk of infection and other adverse effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Lopez, 2015</a>].</li><li><strong>Sexual behaviours </strong>— vulvovaginal candidiasis is not a sexually transmitted infection (STI); however, it can be triggered by sex, especially if there is vaginal dryness and tightness during intercourse. Women receiving oral sex may be at greater risk of vulvovaginal candidiasis, and it can rarely be passed on to sexual partners.</li><li><strong>Contraception </strong>— contraceptive methods may play a part in the development (and also promote recurrences of vulvovaginal candidiasis):<ul><li>Use of spermicidal jellies and creams increases susceptibility to infection by altering the vaginal flora and increasing the adhesion of <em>Candida</em> organisms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Ringdahl, 2000</a>].</li><li>It is thought that women who take oral contraceptive pills, especially combined oral contraceptives (COCs), have a higher rate of vulvovaginal candidiasis, but the evidence for this is contradictory [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Sobel, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">FSRH, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Lopez, 2015</a>]. One theory is that <em>Candida</em> cells have estrogen and progesterone receptors that, when stimulated, increase fungal proliferation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Ringdahl, 2000</a>]. Limited evidence suggests that switching to a progestogen-only injectable contraceptive may help relieve symptoms in women with recurrent vulvovaginal candidiasis; the effect of switching to other progestogen-only forms of contraception is uncertain [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">FSRH, 2012</a>].</li></ul></li><li><strong>Hormone replacement therapy (HRT) </strong>— there is some evidence that postmenopausal women taking HRT are significantly more prone to develop vulvovaginal candidiasis than women who are not, and those who develop vulvovaginal candidiasis are likely to have been susceptible to it before menopause [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Fischer and Bradford, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Fischer and Bradford, 2016</a>]. </li></ul></li><li><strong>The predisposing factors for <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/background-information/definition/\">recurrent</a><em> </em>vulvovaginal candidiasis are uncertain, as the aetiology is poorly understood </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Cooke et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>]<strong>.</strong><ul><li>Possible causes of recurrent vulvovaginal candidiasis include non-compliance with treatment, resistance of non–albicans<em> Candida</em> species (such as <em>Candida glabrata</em>) to conventional imidazole treatment (seen in 10–20% of women with recurrent cases), and continued exposure to risk factors. However, about 50% of women with recurrent cases have no apparent predisposing or underlying conditions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Ringdahl, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>].</li><li>Several theories, such as maladaptive immune response, remain controversial, and the role of individual susceptibility has not yet been defined [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Sobel, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Cooke et al, 2011</a>].</li></ul></li></ul><!-- end field 50298c6c-aa57-4ab2-b36e-74d94f7016bc --><!-- end item b684ecc8-4f08-4474-9796-9c01ed77276f -->","topic":{"id":"99e20f18-68df-560d-b5d3-b6ec31ccad61","topicId":"1a8f74c5-56a3-4356-a328-97bd2f790f35","topicName":"Candida - female genital","slug":"candida-female-genital","lastRevised":"Last revised in May 2017","chapters":[{"id":"de1ba63a-d3be-5e38-9afa-2decfb6a4104","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"70e5dc95-dca6-5aed-ba02-7677e5595791","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7785eebb-7adf-5829-8438-054465d94780","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"17acaa38-dc82-5062-9b9e-b70e43844f09","slug":"changes","fullItemName":"Changes"},{"id":"3fde567e-3066-57d8-be3e-016c389f8b94","slug":"update","fullItemName":"Update"}]},{"id":"7bdd785b-dd70-5bde-a56b-ece7a71c1890","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2aea51d9-2817-5901-8b3f-003e41a1f1b9","slug":"goals","fullItemName":"Goals"},{"id":"16c71775-c8a9-58f1-b6e8-00d83ea3e32a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"584f77ef-93e6-5c84-93b4-8331fed80193","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ffb6e4fa-b86a-5191-9bbb-c113c86952b6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cc13b04c-c8b4-5403-a61e-10f784bc17de","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8ba1a16f-d8bd-55bc-8208-17beaddd9264","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"d90c278f-fcf0-5c7c-aeab-b0decc2194dd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5d851a40-f1f9-50de-b7de-3e374a862b45","slug":"definition","fullItemName":"Definition"},{"id":"51060b0d-4f1d-5133-9645-6efc6b9ca9d8","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c7dd35c5-dc87-55a0-b15e-5fd3c5f79ede","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"bcbc381a-db1c-5df4-a8fa-cb1ce02a4ab3","slug":"complications","fullItemName":"Complications"},{"id":"2ec519a6-61da-53cb-b5c6-e53420e1f175","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"1296609f-72a1-5634-918b-eb0f9bf2b217","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"197fc582-d823-5341-813b-4d48a895ac84","slug":"assessment","fullItemName":"Assessment"},{"id":"7fa609e6-64b1-5e1e-a2fe-9d8aaae57662","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"b7ed2787-e953-5da0-ba29-6ad5d5aa7138","fullItemName":"Management","slug":"management","subChapters":[{"id":"0d8e43cc-e312-572a-97eb-50ab1223bf29","slug":"uncomplicated-infection","fullItemName":"Scenario: Uncomplicated infection"},{"id":"20ef6f32-4f35-577b-af2b-0479dafd7a6f","slug":"severe-infection","fullItemName":"Scenario: Severe infection"},{"id":"19018671-1df6-546c-a24e-c0277342e2e1","slug":"recurrent-infection","fullItemName":"Scenario: Recurrent infection"},{"id":"0f525c4d-623c-5b02-9045-c7f9c57692e4","slug":"diabetes-or-immunocompromised","fullItemName":"Scenario: Diabetes or immunocompromised"},{"id":"d143d272-2856-5fad-95fe-708b221847f0","slug":"during-pregnancy","fullItemName":"Scenario: During pregnancy"}]},{"id":"fa8e2e27-5ea4-5088-86f8-65ffd101ec26","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a11071ae-b868-56f6-a390-4809b91594ea","slug":"choice-of-antifungals","fullItemName":"Choice of antifungals"},{"id":"169ff7be-fabd-556e-bdf3-92c30e390f3d","slug":"intravaginal-antifungals","fullItemName":"Intravaginal antifungals"},{"id":"cca352b0-a363-5b43-97d2-9df0dbf242b6","slug":"oral-fluconazole","fullItemName":"Oral fluconazole"},{"id":"754e0483-3f11-5510-9b98-7f8c44679e56","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"2ae3a41b-64fa-5372-baba-bb8c04e033d8","slug":"topical-antifungals","fullItemName":"Topical antifungals"}]},{"id":"dd75ee8e-5efd-51c0-bcc2-3af7ee1253e7","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"74d9d85c-590f-5e29-a202-78d94a6f747f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d7a69713-bc5d-57da-9132-ff07c7fef62c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a8d93477-c70c-5177-92d7-e96545a6b2f7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4841d69e-1e2b-5aec-9c3b-1ea8cd8bbf08","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b3113b9f-1b0e-5987-99b4-e616eb6d128a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0e41c5da-d9a8-5c0d-bb7f-f68cda4acb05","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6eb1b4a4-5ae4-5a59-8ca6-6434652b9454","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d90c278f-fcf0-5c7c-aeab-b0decc2194dd","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}